Mini, AP Patch Given FDA Nod for Fast-Track Review
A closed-loop patch insulin pump/CGM system has been granted FDA Breakthrough Device Designation by the FDA. The designation is designed to provide a faster track to FDA approval for devices that are considered to provide novel treatment options. The device was created by EOFlow, a company based in South Korea, and the technology was funded […]
The 20th Anniversary of the Edmonton Protocol
This day, 20 years ago, a person with type 1 diabetes (T1D) was cured. Well, pseudo-cured. On March 11, 1999, the Edmonton Protocol had its first participant. This ground-breaking clinical trial was testing a new type of islet transplantation, without corticosteroid immunosuppressive drugs (which is necessary for the prevention of graft rejection). The seven people […]
Insulin Discovered Nearly 100 Years Ago: How Far We’ve Come and the Road Ahead
Incredible strides have been made since the discovery of insulin almost 100 years ago. Insulin formulations have improved dramatically, blood-sugar levels can be measured continuously and first-generation artificial pancreas systems have reached the market. Yet only a small percentage of people with type 1 diabetes (T1D) achieve their blood sugar goals. In a review published […]
JDRF-Backed Start-Up Company to Accelerate Work Through Pfizer
AnTolRx, Inc., a private biotechnology company, has agreed to license its immune tolerance therapy for type 1 diabetes (T1D) to Pfizer with the aim of advancing the research and accelerating its potential for commercialization. The research is part of a larger portfolio of work done by AnTolRx, a Cambridge, Massachusetts-based research and development biotechnology company. […]
Can a Snail Hold the Key to Better Blood Sugar Control?
Helena Safavi, Ph.D., of The University of Utah, decided to take an unusual and creative approach to ultra-rapid insulin development, studying sea snails that use fast-acting insulin, not as a hormone to regulate their blood glucose, but as a toxin to sedate their prey.
Tracking Oxygen Levels Around Transplanted Cells Could Help Build Successful Beta Cell Replacement Therapies
Understanding change in oxygen levels over time in mice may help researchers develop better methods of replacing beta cells in humans.
In First-In-Human Tests, New Artificial Pancreas System Smartphone App Shows Reliable Glucose Control
Artificial pancreas (AP) systems “close the loop” between continuous glucose monitors and insulin pumps using algorithms to manage insulin. Learn more about Breakthrough T1D's funding of groundbreaking AP technology research.
Breakthrough T1D-Funded Researchers Reprogram Human Alpha Cells to Produce Insulin
Human cells, including pancreatic islet cells, are more adaptive than previously believed. Led by Dr. Pedro Herrera at the University of Geneva, Breakthrough T1D-funded researchers demonstrated that transplanted alpha and gamma cells could produce insulin and reverse diabetes in mice.
Multiple Benefits of Screening For Beta Cell Autoimmunity in Children
Learn more about Breakthrough T1D’s prevention research and the benefits of early detection for type 1 diabetes (T1D).
Stem Cells to Beta Cells for Insulin Therapy: One Step Forward by Breakthrough T1D-Funded Researchers
Scientists have made a significant advancement in beta cell replacement research, potentially eliminating the need for insulin therapy for people with type 1 diabetes (T1D). This novel approach could pave the way for effective beta cell replacement therapies, offering hope for those with T1D.
